Clare J. Twist
Clinical Trials
- Not Recruiting Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
- Recruiting Study of MLN8237 in Combination With Irinotecan and Temozolomide
- Recruiting Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
- Recruiting Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
- Recruiting N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
- Recruiting Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
- Not Recruiting ABT-751 With Chemotherapy for Relapsed Pediatric ALL
- Not Recruiting N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
- Not Recruiting Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
- Not Recruiting N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
- Not Recruiting N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma
- Not Recruiting N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
- Not Recruiting Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment
- Not Recruiting Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement
- Not Recruiting N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
- Not Recruiting T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
- Not Recruiting N2001-02: I-Metaiodobenzylguanidine (MIBG) With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
- Not Recruiting Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
- Recruiting Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
Help